Teriflunomide and Its Mechanism of Action in Multiple Sclerosis

    April 2014 in “ Drugs ”
    Amit Bar‐Or, Andrew R. Pachner, Françoise Menguy-Vacheron … Heinz Wiendl
    Studysummary This review discusses the preclinical and clinical data on teriflunomide for multiple sclerosis, highlighting its selective action on immune cells without causing clinical immune suppression, and provides no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Chemotherapy-Induced Alopecia: Emotional Distress and Mitigation Strategies Seminars in Cutaneous Medicine and Surgery · 2009